EI Cure Project’s Post

We recently we had the great pleasure of meeting with some of the world’s leading experts in the fields of #Dermatology and #AtopicDermatitis, to discuss clinical development plans for the lead candidate in our pipeline of disease-modifying #Therapies for chronic #Autoimmune and #InflammatoryDiseases. SYX-5219, which will advance into the clinic for the treatment of atopic dermatitis, targets a critical enzyme regulating cell #Metabolism called pyruvate kinase M2 (PKM2) – a novel therapeutic target with the potential to rebalance the #ImmuneSystem, normalize immune cell function and drive sustained disease remission.    As we finalise our development plans for this candidate, it’s vital that we collaborate with, and learn from, those who are expert in the field and those who are treating patients today. A huge thank you to everyone who shared their time, knowledge, insights and real-world experiences – invaluable to us in ensuring our #Science can continue to progress at pace for the benefit of patients.   Find out more about the latest progress within Sitryx’s proprietary pipeline: https://lnkd.in/eS8FGNRx

Exciting News! 🚀 Lynx is expanding our data offerings in a new way, adding Dermatology as one of our key specialty areas. Unstructured notes and reports provides life sciences with a robust picture of dermatologic disease activity, location of disease, %BSA impacted, and many other clinical outcomes measures. Key diseases include (but are not limited to): dermatitis, vitiligo, psoriasis, skin malignancies, HS, and alopecia. If you are working in the inflammation and immunology space and have not yet heard of Lynx.MD, now is the time for an intro before you fall behind. Dermatology ✅ Gastroenterology ✅ ENT / Allergy / Asthma ✅

𝑪𝒀𝑴𝑩𝑰𝑶𝑻𝑰𝑪𝑺 𝑺𝑲𝑰𝑵-𝑯𝑬𝑨𝑳𝑻𝑯 𝑰𝑵𝑺𝑰𝑮𝑯𝑻𝑺 📝 Exploring the Transcriptional Landscape of the Human Sebaceous Gland Sebaceous glands (SGs) play a crucial role in maintaining skin health, but when their function is disrupted, it can lead to skin disorders like acne and affect broader physiological processes. Researchers in this study, offer the first high-resolution map of sebaceous differentiation using advanced spatial transcriptomics, pseudotime analysis, RNA velocity, and functional enrichment methods. Discover how this research unravels the stages of sebocyte differentiation, highlights key gene expression changes, and opens doors to novel therapeutic targets for skin disorders. Dive in to explore the future of sebaceous gland research and its implications for dermatology: https://lnkd.in/gUXDAsDn #Dermatology #Research #SkinResearch #Transcriptomics #SkinHealth #SkinDisorder #Biotechnology #Biopharma #Innovation #Cymbiotics DAYLAN P., Maneesh Paul. S., M. Sc., Ph.D., FIDSA., Rachana B Urs, Manuela Saakshi Maria Schmidt, Florian Hansmann, Henry Löffler-Wirth, Christos C. Prof. Dr. Zouboulis

AMLo Biosciences issued a news release this week announcing that #AMLBLor received its #UKCA mark making it available to NHS and private hospitals. AMBLor is an innovative histopathological biomarker for early-stage #melanoma. It accurately identifies the presence of two prognostic proteins, AMBRA1 and loricrin, in the skin overlying the tumour. The presence of one or both biomarkers is associated with a low risk of progression. This additional prognostic information could help reduce the burden of procedures and appointments on both patients and stretched healthcare resources, and provide a more tailored management approach. Read the full press release: https://bit.ly/479VHJK #dermatology #dermatopathology #histopathology #histology #oncology #skincancer #cancerresearch #biomarkers #prognostics #healthinvestment

Under the motto “Uncovering the Broad Spectrum of Psoriatic Disease” the 7th World Psoriasis & Psoriatic Arthritis Conference took place last week in Stockholm. The focus of the conference is to improve the lives of patients living with psoriatic disease by sharing significant achievements in the prevention, diagnosis, and treatment. With PsorX-LabDisk, we support dermatopathologists in the differential diagnosis of psoriasis and eczema - as there are still up to 50% misdiagnoses of the two skin diseases due to overlapping clinical and histological appearances. However, the feedback from the dermatologists at the conference was clear: ❗This is not enough❗The test needs to be introduced into dermatologists' practices for use at the point of care. How good that work on it is already in full swing in the Dermagnostix R&D team!💪🚀 This feedback once again reinforces our belief in the urgent need for molecular diagnostics for inflammatory skin diseases - both for dermatologists and pathologists. 💡You want to be part of the #DermagnosticFuture? Schedule a meeting with us now to learn more about PsorX: https://lnkd.in/egn75BGc #MolecularDiagnostics #Psoriasis #PsorX #Dermatology #Innovation #IFPA

#Hotoff_the_press: Proud of the dynamic duo Mahdi Saghari and Wouter ten Voorde who #together dedicated their last 6 years to innovate #clinicalpharmacology, #immunology and #skinscience with novel pharmacological models (#KLH, #SubstanceP, #imiquimod and #LPS) in healthy volunteers. The effects were monitored by various (non)invasive techniques, and serve as pharmacodynamic endpoints in early-phase #clinicalstudies of immunomodulatory compounds. Their work resulted in two excellent #PhD_theses: 'Keyhole limpet hemocyanin challenge model for studying adaptive immune responses in early-phase clinical drug development' & 'Rubor, Calor, Tumor, Dolor. Objective assessments of inflammation’ The public #double #PhDdefence will take place on #December17th at 10.00 am (Mahdi) and 13.00 (Wouter) at Leiden University. Please ping me if you would like to receive their theses! #Teamscience #Dermatology Centre for Human Drug Research Erasmus MC Department of Dermatology Leiden University Medical Center

The latest #psoriasis slide decks are now available on the #IMIDForum! Explore new insights and data to enhance your practice with the top research in #dermatology: [LINK] This month’s Literature Highlights are now available on the Immune-Mediated Inflammatory Disease Forum! November’s single slide summary includes a study by Huang, et al., where they aimed to identify predictors and construct a predictive model for time to relapse following withdrawal from biologics. Find out more about this publication, and more about #psoriasis on the IMID Forum today. 🔗https://ow.ly/z06850UhCMV

This year’s Annual Meeting of the British Association of Dermatologists (BAD) is being held in Manchester on 2-4 July. Jude Kilbee and Jane Meaney will be hosting AMLo Biosciences’ exhibition stand E3, so stop by to find out more about our work with prognostic biomarkers One of our developed technologies identifies early-stage #melanomas at genuine low-risk of metastasis. Our ongoing research is looking at identifying at-risk and high-risk melanomas. Come and chat about how this additional prognostic information can help inform clinical decision making and aid in alleviating some patient anxiety around disease progression. amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

Here at AMLo Biosciences we acknowledge how real the fears that accompany a #melanoma diagnosis can be. Anxiety arising from Financial Toxicity (financial distress) for those diagnosed with any cancer can have a significant adverse effect on quality of life that can manifest in many ways including: ·    Poor physical health ·    Poor mental health and depression ·    Social distress ·    Family distress https://bit.ly/49JxxWs We have developed a prognostic test, #AMBLor, to help reduce the anxiety associated with a #melanoma diagnosis. By identifying those at low risk of progression at an early stage, we aim to reduce the physiological and psychological burden and offer some reassurance for what the future may hold. For further information about the benefits of AMBLor, take a look at our website www.amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers  

🎉 A Breakthrough in Treating Deadly Skin Disease: World-First Cure Achieved! In an incredible leap forward for medical science, researchers have successfully cured patients suffering from Toxic Epidermal Necrolysis (TEN), a rare and often fatal skin condition, through an innovative use of existing drugs. Published in Nature, this landmark study could pave the way for an approved curative therapy, offering hope where there was previously very little. 🔬 Study Highlights: ◾ TEN, characterized by severe skin blistering and a high mortality rate, was halted using JAK inhibitors, drugs already used for inflammatory diseases. ◾ The study not only saved lives but also opened new doors in the treatment of other severe skin disorders and inflammatory conditions. 🌍 Global Impact: This pioneering work represents a monumental step in dermatology and emergency medicine, showcasing the power of collaborative research and the repurposing of drugs to fast-track life-saving treatments. 🔗 https://lnkd.in/grttG9-Q #MedicalResearch #Dermatology #HealthcareInnovation #SkinDisease #LifeSavingResearch